Indivior PLC (NASDAQ:INDV) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Indivior PLC (NASDAQ:INDV) have received an average recommendation of “Moderate Buy” from the seven ratings firms that are covering the firm, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $45.1667.

INDV has been the topic of several recent analyst reports. Weiss Ratings downgraded shares of Indivior from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Friday. Zacks Research cut shares of Indivior from a “strong-buy” rating to a “hold” rating in a research note on Monday, June 29th. Craig Hallum reiterated a “buy” rating and set a $53.00 price target on shares of Indivior in a report on Tuesday, August 4th. Finally, Barclays reduced their price objective on shares of Indivior from $46.00 to $43.00 and set an “overweight” rating on the stock in a research report on Wednesday, August 5th.

Indivior Stock Performance

NASDAQ INDV opened at $35.97 on Wednesday. The company has a market cap of $4.24 billion, a P/E ratio of 12.89 and a beta of 0.86. The business’s 50 day moving average price is $39.50 and its 200-day moving average price is $35.99. Indivior has a fifty-two week low of $22.22 and a fifty-two week high of $42.81.

Indivior (NASDAQ:INDV) last released its quarterly earnings results on Tuesday, June 30th. The company reported $5.75 earnings per share for the quarter. The company had revenue of $343.00 million for the quarter. Indivior had a negative return on equity of 283.11% and a net margin of 26.65%. As a group, equities analysts predict that Indivior will post 3.66 EPS for the current year.

Insider Activity

In related news, CFO Ryan Preblick sold 36,000 shares of the firm’s stock in a transaction that occurred on Monday, June 8th. The stock was sold at an average price of $37.70, for a total transaction of $1,357,200.00. Following the completion of the sale, the chief financial officer directly owned 284,751 shares of the company’s stock, valued at approximately $10,735,112.70. This trade represents a 11.22% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Woodrow D. Anderson acquired 1,500 shares of the company’s stock in a transaction that occurred on Wednesday, August 5th. The shares were acquired at an average price of $36.28 per share, with a total value of $54,420.00. Following the acquisition, the chief accounting officer owned 26,138 shares in the company, valued at $948,286.64. This trade represents a 6.09% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders own 0.74% of the company’s stock.

Institutional Trading of Indivior

Hedge funds and other institutional investors have recently bought and sold shares of the business. Quarry LP purchased a new stake in shares of Indivior during the third quarter valued at $26,000. Raymond James Financial Inc. purchased a new position in Indivior in the 2nd quarter worth about $26,000. Caitong International Asset Management Co. Ltd lifted its holdings in Indivior by 72.7% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,093 shares of the company’s stock valued at $39,000 after buying an additional 460 shares in the last quarter. Rockefeller Capital Management L.P. lifted its holdings in Indivior by 512.4% during the 4th quarter. Rockefeller Capital Management L.P. now owns 1,286 shares of the company’s stock valued at $46,000 after buying an additional 1,076 shares in the last quarter. Finally, TD Waterhouse Canada Inc. purchased a new stake in Indivior in the 2nd quarter valued at about $63,000. Hedge funds and other institutional investors own 60.33% of the company’s stock.

About Indivior

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.